{"id":96805,"date":"2026-08-04T03:24:11","date_gmt":"2026-08-04T03:24:11","guid":{"rendered":"https:\/\/www.europesays.com\/britain\/96805\/"},"modified":"2026-08-04T03:24:11","modified_gmt":"2026-08-04T03:24:11","slug":"a-merged-astrazeneca-and-bms-could-lead-lilly-on-revenue-until-about-2030","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/britain\/96805\/","title":{"rendered":"A merged AstraZeneca and BMS could lead Lilly on revenue until about 2030"},"content":{"rendered":"

\"\"In a potential marriage that analysts said faces long odds, AstraZeneca and Bristol Myers Squibb have held talks on a merger that would create the world\u2019s largest drugmaker by revenue and rank among the biggest deals in pharmaceutical history, the Financial Times<\/a> reported.<\/p>\n

The merger would also mark the most significant reshaping of pharma\u2019s top tier since Lilly jumped from ninth-largest to the top slot by revenue on the strength of its metabolic franchise. It claimed the top spot with $65.18 billion, roughly two-thirds of the $100.33 billion Pfizer booked at its pandemic peak in 2022.<\/p>\n

A combined AstraZeneca and BMS would reset that bar. The company would hold one of the industry\u2019s broadest oncology portfolios, pairing AstraZeneca\u2019s Tagrisso, Imfinzi and Calquence and the Daiichi Sankyo-partnered ADCs Enhertu and Datroway<\/a> with BMS\u2019s Opdivo, Yervoy and Opdualag<\/a>, while adding BMS\u2019s hematology, cell therapy and neuroscience franchises to AstraZeneca\u2019s current mix. Based on their FY2025 filings, the pair would have spent $24.18 billion on R&D, above every standalone company in the Pharma 50 data. Reported spending among Roche<\/a>, Lilly<\/a>, J&J<\/a> and Merck<\/a> ranged from $12.52 billion to $15.79 billion, although acquired in-process R&D and differences in reporting scope make the comparison approximate.<\/p>\n

AstraZeneca and BMS generated a combined $106.94 billion in 2025, compared with Lilly\u2019s $65.18 billion. Current AstraZeneca<\/a> and BMS<\/a> guidance and an R&D World model of Lilly\u2019s full-year revenue, built from its reported first quarter<\/a> and historical quarterly pattern, put 2026 revenue at roughly $112.6 billion for the hypothetical combination and $87 billion for Lilly. That would leave Lilly growing about 33% this year against roughly 5% for the merged pair. Running both forward, the model puts the median crossover around 2030; in about a third of simulations, the merged company remained ahead in 2032 or later.<\/p>\n

Analysts remained skeptical. Jefferies analysts led by Michael Leuchten wrote that they were \u201ca bit perplexed\u201d<\/a> given AstraZeneca\u2019s growth and innovation profile, adding that if any company does not need financial engineering, it is AstraZeneca. Citi called the report a surprise given the pipeline. RBC told clients<\/a> that agreeing on value may prove difficult. BMO Capital Markets<\/a> wrote that significant business overlap makes a deal less likely to materialize and estimated deal capacity at roughly $32 billion for BMS and $37 billion for AstraZeneca, meaning neither can buy the other outright.<\/p>\n

Note about the projections. FY2024 and FY2025 revenue and R&D figures come from R&D World\u2019s Pharma 50 datasets, compiled from company filings and annual reports. Non-USD figures were converted at IRS annual-average exchange rates. Division revenue was used for diversified companies where available; R&D scope varies by company and is flagged in the underlying data. AstraZeneca\u2019s FY2026 estimate applies a 6% to 9% growth range to FY2025 revenue, and BMS uses the midpoint of its current $49 billion to $50 billion guidance; both were checked against reported first-half results. Lilly\u2019s FY2026 estimate comes from Monte Carlo simulations anchored to reported Q1 revenue and the 2024\u20132025 quarter-to-quarter pattern. A scenario parameter controls how much of that pattern repeats, with quarterly variation added. Using reported quarterly figures, the model yielded a median of $86.9 billion and a central 80% interval of $81.0 billion to $94.1 billion, compared with Lilly\u2019s $82 billion to $85 billion guidance. For 2027 onward, the model centers Lilly\u2019s growth at 13% in 2027, tapering to roughly 7% by 2033, and the combination\u2019s growth at 4.5% a year. It assumes no divestitures or merger-related revenue attrition. Of course, pipeline changes and other factors can make long-term projections inaccurate. Lilly reports second-quarter results Aug. 5.<\/p>\n

Filed Under: Pharma 50<\/a>
Tagged With: analyst skepticism<\/a>, AstraZeneca<\/a>, Big Pharma<\/a>, BMS<\/a>, Bristol-Myers Squibb<\/a>, Calquence<\/a>, Datroway<\/a>, deal capacity<\/a>, Eli Lilly<\/a>, Enhertu<\/a>, financial engineering<\/a>, Imfinzi<\/a>, Monte Carlo model<\/a>, oncology portfolio<\/a>, Opdivo<\/a>, Opdualag<\/a>, pharma merger<\/a>, pharmaceutical industry<\/a>, R&D spending<\/a>, revenue forecast<\/a>, Tagrisso<\/a>, Yervoy<\/a>
\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"In a potential marriage that analysts said faces long odds, AstraZeneca and Bristol Myers Squibb have held talks…\n","protected":false},"author":2,"featured_media":96806,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[20662],"tags":[41065,11153,41066,41067,40798,41068,24174,41069,28606,21722,41070,25687,41071,40799,40802,41072,41073,40794,41074,41075,34155,41076],"class_list":["post-96805","post","type-post","status-publish","format-standard","has-post-thumbnail","category-astrazeneca","tag-analyst-skepticism","tag-astrazeneca","tag-big-pharma","tag-bms","tag-bristol-myers-squibb","tag-calquence","tag-datroway","tag-deal-capacity","tag-eli-lilly","tag-enhertu","tag-financial-engineering","tag-imfinzi","tag-monte-carlo-model","tag-oncology-portfolio","tag-opdivo","tag-opdualag","tag-pharma-merger","tag-pharmaceutical-industry","tag-rd-spending","tag-revenue-forecast","tag-tagrisso","tag-yervoy"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@UnitedKingdom\/117035104232189313","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts\/96805","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/comments?post=96805"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts\/96805\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/media\/96806"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/media?parent=96805"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/categories?post=96805"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/tags?post=96805"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}